Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxcarbazepine
Drug ID BADD_D01637
Description Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L863] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine].[A186011] Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing to its primarily reductive metabolism.[A186032]
Indications and Usage For use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy.
Marketing Status Prescription; Discontinued
ATC Code N03AF02
DrugBank ID DB00776
KEGG ID D00533
MeSH ID D000078330
PubChem ID 34312
TTD Drug ID D0QL3P
NDC Product Code 55289-007; 76047-001; 48087-0115; 71335-0144; 31722-023; 82334-001; 48087-0046; 68084-867; 48087-0158; 55512-0018; 50268-649; 55154-8198; 66406-0246; 63629-3816; 68462-137; 70518-1842; 50090-5003; 66406-0245; 65372-1104; 51991-293; 51508-008; 51991-292; 51672-4105; 68084-845; 70518-2253; 71428-007; 55512-0017; 70518-2377; 70518-2276; 51672-4106; 71335-0505; 55154-8187; 17772-122; 50383-312; 68084-853; 58159-088; 60429-061; 70518-3237; 72189-339; 55512-0006; 0615-8292; 66406-0244; 70518-3127; 68788-7866; 68462-138; 17772-123; 51672-4107; 63629-2075; 0615-8153; 48087-0118; 68462-139; 31722-025; 48087-0157; 66039-905; 0078-0456; 69766-055; 55512-0008; 70518-1027; 70518-0894; 0781-6270; 71205-411; 70518-1055; 42419-006; 0078-0457; 48087-0114; 71335-0090; 62756-183; 0078-0337; 70518-2254; 60429-062; 62512-0058; 31722-024; 55512-0023; 55512-0016; 68094-123; 55700-868; 60429-063; 51991-294; 72761-033; 0054-0199; 55512-0007; 63629-4987; 63629-6834; 42419-029; 70518-2370; 17772-121; 62756-185; 0078-0357; 70966-0004; 62756-184; 70518-1980; 70518-3197; 12658-0588; 65162-649
Synonyms Oxcarbazepine | 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide | Trileptal | Timox | GP 47680
Chemical Information
Molecular Formula C15H12N2O2
CAS Registry Number 28721-07-5
SMILES C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Multiple organ dysfunction syndrome08.01.03.0570.000434%
Bicuspid aortic valve03.07.05.003; 02.07.03.0070.000831%Not Available
Coeliac disease10.04.04.012; 07.17.01.008; 14.02.01.0070.002078%Not Available
Congenital aortic stenosis24.04.01.006; 03.07.08.0050.000831%Not Available
Congenital mitral valve incompetence03.07.05.007; 02.07.01.0040.000831%Not Available
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.000831%Not Available
Epileptic aura17.12.03.0240.000831%Not Available
Immunodeficiency common variable10.03.01.0060.002078%Not Available
Micrognathia15.11.05.007; 03.11.05.0070.001247%Not Available
Neonatal respiratory distress syndrome22.11.02.010; 18.04.10.0030.001247%Not Available
Oral lichen planus23.03.08.012; 07.05.01.0180.000831%Not Available
Pneumonia haemophilus22.07.06.013; 11.02.15.0020.002078%Not Available
Renal hypertension24.08.08.002; 20.01.08.0050.000831%Not Available
Small for dates baby18.04.02.0020.001247%Not Available
Speech disorder developmental19.19.01.003; 17.02.08.0110.000831%Not Available
Acinetobacter infection11.02.01.0330.001247%Not Available
Splenic lesion01.09.02.0170.000831%Not Available
Anticonvulsant drug level below therapeutic13.17.01.0230.000831%Not Available
Eosinophilic colitis07.08.01.019; 01.02.04.0150.000831%Not Available
Anticonvulsant drug level decreased13.17.01.0240.002078%Not Available
Multi-organ disorder08.01.03.0740.000217%Not Available
Sopor19.02.04.002; 17.02.04.0210.001247%Not Available
Blood chromogranin A increased13.10.02.0120.000831%Not Available
Klebsiella infection11.02.03.0030.000831%Not Available
Congenital nose malformation22.10.02.003; 03.16.04.0010.000831%Not Available
Acute hepatitis C11.05.06.007; 09.01.09.0110.000831%Not Available
Fear of death19.06.03.0060.000831%Not Available
Congenital tricuspid valve incompetence03.07.05.012; 02.07.05.0030.000831%Not Available
Congenital inguinal hernia07.16.02.003; 03.04.07.0050.000831%Not Available
Seizure cluster17.12.03.0290.000831%Not Available
The 18th Page    First    Pre   18 19    Next   Last    Total 19 Pages